vs
Side-by-side financial comparison of BRUKER CORP (BRKR) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
BRUKER CORP is the larger business by last-quarter revenue ($977.2M vs $62.1M, roughly 15.7× Cytek Biosciences, Inc.). BRUKER CORP runs the higher net margin — 2.7% vs -70.9%, a 73.6% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -0.2%). BRUKER CORP produced more free cash flow last quarter ($207.2M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 16.4%).
Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts, and is the publicly traded parent company of Bruker Scientific Instruments and Bruker Energy & Supercon Technologies (BEST) divisions.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
BRKR vs CTKB — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $977.2M | $62.1M |
| Net Profit | $26.0M | $-44.1M |
| Gross Margin | 46.0% | 52.9% |
| Operating Margin | 7.8% | -9.0% |
| Net Margin | 2.7% | -70.9% |
| Revenue YoY | -0.2% | 8.1% |
| Net Profit YoY | 89.8% | -557.1% |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $977.2M | $62.1M | ||
| Q3 25 | $860.5M | $52.3M | ||
| Q2 25 | $797.4M | $45.6M | ||
| Q1 25 | $801.4M | $41.5M | ||
| Q4 24 | $979.6M | $57.5M | ||
| Q3 24 | $864.4M | $51.5M | ||
| Q2 24 | $800.7M | $46.6M | ||
| Q1 24 | $721.7M | $44.9M |
| Q4 25 | $26.0M | $-44.1M | ||
| Q3 25 | $-59.6M | $-5.5M | ||
| Q2 25 | $7.6M | $-5.6M | ||
| Q1 25 | $17.4M | $-11.4M | ||
| Q4 24 | $13.7M | $9.6M | ||
| Q3 24 | $40.9M | $941.0K | ||
| Q2 24 | $7.6M | $-10.4M | ||
| Q1 24 | $50.9M | $-6.2M |
| Q4 25 | 46.0% | 52.9% | ||
| Q3 25 | 44.1% | 52.7% | ||
| Q2 25 | 44.9% | 52.3% | ||
| Q1 25 | 48.8% | 48.6% | ||
| Q4 24 | 50.4% | 58.5% | ||
| Q3 24 | 48.4% | 56.3% | ||
| Q2 24 | 48.0% | 54.6% | ||
| Q1 24 | 48.9% | 51.3% |
| Q4 25 | 7.8% | -9.0% | ||
| Q3 25 | -6.0% | -17.6% | ||
| Q2 25 | 1.5% | -23.3% | ||
| Q1 25 | 4.0% | -36.1% | ||
| Q4 24 | 7.4% | 5.2% | ||
| Q3 24 | 7.9% | -8.2% | ||
| Q2 24 | 6.0% | -18.3% | ||
| Q1 24 | 9.0% | -23.9% |
| Q4 25 | 2.7% | -70.9% | ||
| Q3 25 | -6.9% | -10.5% | ||
| Q2 25 | 1.0% | -12.2% | ||
| Q1 25 | 2.2% | -27.5% | ||
| Q4 24 | 1.4% | 16.8% | ||
| Q3 24 | 4.7% | 1.8% | ||
| Q2 24 | 0.9% | -22.4% | ||
| Q1 24 | 7.1% | -13.8% |
| Q4 25 | $0.10 | — | ||
| Q3 25 | $-0.41 | — | ||
| Q2 25 | $0.05 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.09 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $0.05 | — | ||
| Q1 24 | $0.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $298.8M | $90.9M |
| Total DebtLower is stronger | $1.9B | — |
| Stockholders' EquityBook value | $2.5B | $341.7M |
| Total Assets | $6.2B | $461.5M |
| Debt / EquityLower = less leverage | 0.76× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $298.8M | $90.9M | ||
| Q3 25 | $293.1M | $93.3M | ||
| Q2 25 | $92.0M | $75.5M | ||
| Q1 25 | $184.2M | $95.3M | ||
| Q4 24 | $183.4M | $98.7M | ||
| Q3 24 | $148.1M | $162.3M | ||
| Q2 24 | $169.7M | $177.9M | ||
| Q1 24 | $340.1M | $168.8M |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $2.5B | $341.7M | ||
| Q3 25 | $2.4B | $378.6M | ||
| Q2 25 | $1.8B | $377.6M | ||
| Q1 25 | $1.8B | $379.6M | ||
| Q4 24 | $1.8B | $395.7M | ||
| Q3 24 | $1.8B | $385.5M | ||
| Q2 24 | $1.8B | $389.1M | ||
| Q1 24 | $1.4B | $392.6M |
| Q4 25 | $6.2B | $461.5M | ||
| Q3 25 | $6.4B | $494.9M | ||
| Q2 25 | $6.3B | $493.3M | ||
| Q1 25 | $5.9B | $482.6M | ||
| Q4 24 | $5.8B | $499.5M | ||
| Q3 24 | $6.1B | $491.2M | ||
| Q2 24 | $5.9B | $483.7M | ||
| Q1 24 | $4.5B | $492.1M |
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.8M | $-771.0K |
| Free Cash FlowOCF − Capex | $207.2M | $-1.8M |
| FCF MarginFCF / Revenue | 21.2% | -2.9% |
| Capex IntensityCapex / Revenue | 2.3% | 1.6% |
| Cash ConversionOCF / Net Profit | 8.84× | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.3M | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.8M | $-771.0K | ||
| Q3 25 | $-33.2M | $-3.9M | ||
| Q2 25 | $-127.5M | $108.0K | ||
| Q1 25 | $65.0M | $-125.0K | ||
| Q4 24 | $190.0M | $2.0M | ||
| Q3 24 | $38.4M | $13.2M | ||
| Q2 24 | $1.1M | $6.2M | ||
| Q1 24 | $21.8M | $4.0M |
| Q4 25 | $207.2M | $-1.8M | ||
| Q3 25 | $-54.1M | $-4.6M | ||
| Q2 25 | $-148.8M | $-1.5M | ||
| Q1 25 | $39.0M | $-974.0K | ||
| Q4 24 | $153.3M | $1.1M | ||
| Q3 24 | $5.8M | $12.2M | ||
| Q2 24 | $-23.5M | $5.2M | ||
| Q1 24 | $400.0K | $3.4M |
| Q4 25 | 21.2% | -2.9% | ||
| Q3 25 | -6.3% | -8.7% | ||
| Q2 25 | -18.7% | -3.2% | ||
| Q1 25 | 4.9% | -2.3% | ||
| Q4 24 | 15.6% | 1.9% | ||
| Q3 24 | 0.7% | 23.7% | ||
| Q2 24 | -2.9% | 11.0% | ||
| Q1 24 | 0.1% | 7.6% |
| Q4 25 | 2.3% | 1.6% | ||
| Q3 25 | 2.4% | 1.3% | ||
| Q2 25 | 2.7% | 3.5% | ||
| Q1 25 | 3.2% | 2.0% | ||
| Q4 24 | 3.7% | 1.6% | ||
| Q3 24 | 3.8% | 2.0% | ||
| Q2 24 | 3.1% | 2.3% | ||
| Q1 24 | 3.0% | 1.3% |
| Q4 25 | 8.84× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.78× | — | ||
| Q1 25 | 3.74× | — | ||
| Q4 24 | 13.87× | 0.21× | ||
| Q3 24 | 0.94× | 14.05× | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
